Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Burixafor ( GPC-100 ) Phase 2 Trial in Multiple Myeloma Nears Key Readout ...
Price Over Earnings Overview: Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )
In the current session, Bristol-Myers Squibb Inc. ( NYSE:BMY ) is trading at $45.73, after a 3.58% decrease. Over the past month, the stock decreased by 2.06%, and in the past year, by 15.25%. With performance like this, long-term shareholders are more likely to start looking into the company's ...
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
Chinese healthcare, biotech firms flock to Hong Kong for IPOs
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, ...
Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - GSK ( NYSE:GSK ) , Bristol-Myers Squibb ( NYSE:BMY )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Bristol Myers Squibb ( BMY ) Beats Stock Market Upswing: What Investors Need to Know
Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to its last close.
Bristol Myers Squibb Company ( BMY ) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
REDWOOD CITY, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role ...
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says Analyst - Eli Lilly ( NYSE:LLY ) , Bristol-Myers Squibb ( NYSE:BMY )
President Donald Trump's proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Bristol Myers Squibb ( BMY ) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $44.16, indicating a -1.67% shift from the previous trading day.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
The Smartest Dividend Stock to Buy With $1,000 Right Now
Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.
Bristol Myers Squibb Gains on Phase 3 Myeloma Data - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb & Co. BMY on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator ( CELMoD ) , combined with standard therapies ( daratumumab + dexamethasone ) in patients with relapsed or refractory multiple ...
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
MAINZ, Germany, September 23, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) , alongside its artificial intelligence ( "AI" ) company InstaDeep Ltd. ( "InstaDeep" ) , will host its second AI Day, an edition of BioNTech's "Innovation Series", at 09:00 a.m. EDT ( 3:00 p.m.
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
SAN DIEGO, Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive ...
Bull of the Day: Halozyme Therapeutics ( HALO )
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth ...
1 Reason to Buy Bristol Myers Squibb Stock
Find out why investors seeking passive income want shares of this dividend payer in their portfolio.
Fortrea Appoints William Sharbaugh to Board of Directors - Fortrea Holdings ( NASDAQ:FTRE )
DURHAM, N.C., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Fortrea FTRE ( the "Company" ) , a leading global contract research organization ( CRO ) , today announced the appointment of William Sharbaugh to the Company's Board of Directors.
Fortrea Appoints William Sharbaugh to Board of Directors
DURHAM, N.C., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Fortrea ( Nasdaq: FTRE ) ( the "Company" ) , a leading global contract research organization ( CRO ) , today announced the appointment of William Sharbaugh to the Company's Board of Directors.
Bristol Myers Squibb ( BMY ) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $45.6, denoting a -1.19% move from the preceding trading day.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials - Johnson & Johnson ( NYSE:JNJ )
Icotrokinra outperformed deucravacitinib in skin clearance at Weeks 16 and 24 with similar or fewer adverse events. At Week 52, 86% of adolescents on icotrokinra achieved PASI 90 response, showing sustained effectiveness. Up Next: Wall Street trader's 34-0 strategy goes public this week.
3 Great High-Yield Dividend Stocks to Buy in September
Quality yields above 6% from three very different market sectors.
Global Psychotic Disorders Market Poised For Significant Growth
The global market for medications addressing psychotic disorders is projected to reach $32.1 billion by 2033, exhibiting a robust compound annual growth rate ( CAGR ) of 6.5% over the forecast period.
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
SEATTLE, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( "Perspective" or the "Company" ) ( NYSE AMERICAN: CATX ) , a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a ...
Bristol Myers Squibb Company ( BMY ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
Chinese drug makers put on brave face after report says Trump mulling curbs
Chinese drug makers put on a brave face in the wake of a report that said the Trump administration was considering new restrictions on China-developed medicines, citing the country's supply chain and cost advantages, according to executives at a forum in Hong Kong on Thursday.
Bristol Myers Squibb ( BMY ) Outperforms Broader Market: What You Need to Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $47.23, marking a +1.09% move from the previous day.
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz - iShares Biotechnology ETF ( NASDAQ:IBB ) , SPDR Series Trust SPDR S&P Biotech ETF ( ARCA:XBI )
About $350 billion U.S. biotech investments point to long-term upside in pharma ETFs and domestic growth stocks. J&J, Novartis, Eli Lilly, AstraZeneca, and BMS are leading expansions creating thousands of jobs. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Bristol-Myers Squibb ( NYSE:BMY ) , BioNTech ( NASDAQ:BNTX )
A 76.3% overall response rate and a 100% disease control rate were seen in 38 evaluable ES-SCLC patients. Median progression-free survival of 6.8 months with tumor shrinkage averaging 56.7%. Get the data-driven signals to profit from September volatility ( for free ) →
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig ( BNT327/BMS986545 ) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
MAINZ, Germany, and PRINCETON, USA, September 8, 2025 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) and Bristol Myers Squibb Company ( NYSE: BMY, "BMS" ) today presented interim data from a global randomized Phase 2 trial ( NCT06449209 ) evaluating pumitamig ( also known as BNT327 or BMS986545 ) , ...
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Is Pfizer a Millionaire Maker?
Pfizer's stock is down nearly 60% from its post-pandemic peak, opening up an opportunity for the right long-term investors.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Pfizer ( NYSE:PFE ) , Bristol-Myers Squibb ( NYSE:BMY )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug - Zai Lab ( NASDAQ:ZLAB ) , Amgen ( NASDAQ:AMGN )
The final analysis of the Phase 3 trial showed reduced survival benefits from bemarituzumab. FORTITUDE-102 readout expected by late 2025 or early 2026 before regulatory filing. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) On Wednesday, Amgen Inc.
Insider Decision: David V Elkins Offloads $2.65M Worth Of Bristol-Myers Squibb Stock - Bristol-Myers Squibb ( NYSE:BMY )
Making a noteworthy insider sell on September 3, David V Elkins, EVP at Bristol-Myers Squibb BMY, is reported in the latest SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Elkins sold 56,000 shares of Bristol-Myers Squibb.
2 Top Dividend Stocks to Buy With Less Than $50
These stocks are cheap in more ways than one.
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?
Prothena ( PRTA ) Up 17.6% Since Last Earnings Report: Can It Continue?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - Adagene ( NASDAQ:ADAG )
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene" ) ADAG, a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.
